Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-δ (PKC-δ) signal pathway

Journal of Cellular Biochemistry

Volumn 101, Issue 4, 2007, Pages 987-995

  Kim, Young Ho ^a   Jun, Hee Lim ^a   Lee, Tae Jin ^a   Park, Jong Wook ^a   Taeg, Kyu Kwon ^a  

^a Keimyung University   (South Korea)

Author keywords

Apicidin; Cyclin D3; HDAC inhibitor; PKC ; Sp1; TSA

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APICIDIN; CYCLIN D3; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C DELTA; ROTTLERIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; COLON CANCER; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ACETOPHENONES; BENZOPYRANS; BINDING SITES; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CYCLIN A; CYCLINS; GENE EXPRESSION; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; LUCIFERASES; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES, CYCLIC; PROMOTER REGIONS (GENETICS); PROTEIN KINASE C-DELTA; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION;

EID: 34447290046     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21316     Document Type: Article

References (28)

1. Espinos E, Weber MJ. 1998. Activation of the MAP kinase cascade by histone deacetylase inhibitors is required for the stimulation of choline acetyltransferase gene promoter. Brain Res Mol Brain Res 56:118-124.
2. Florenes VA, Skrede M, Jorgensen K, Nesland JM. 2004. Deacetylase inhibition in malignant melanomas: Impact on cell cycle regulation and survival. Melanoma Res 14: 173-181.
3. Gray SG, Teh BT. 2001. Histone acetylation/deacetylation and cancer: An "open" and "shut" case? Curr Mol Med 1: 401-429.
4. Gregory PD, Wagner K, Horz W. 2001. Histone acetylation and chromatin remodeling. Exp Cell Res 265:195-202.
5. Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW. 2001. Activation of p21(WAF1/ Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: Involvement of protein kinase C. J Biol Chem 276:42084-42090.
6. Hong J, Ishihara K, Yamaki K, Hiraizumi K, Ohno T, Ahn JW, Zee O, Ohuchi K. 2003. Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells. Cancer Lett 189:197-206.
7. Hou M, Wang X, Popov N, Zhang A, Zhao X, Zhou R, Zetterberg A, Bjorkholm M, Henriksson M, Gruber A, Xu D. 2002. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274:25-34.
8. Kalkhoven E. 2004. CBP and p300: HATs for different occasions. Biochem Pharmacol 68:1145-1155.
9. Kim YK, Han JW, Woo YN, Chun JK, Yoo JY, Cho EJ, Hong S, Lee HY, Lee YW, Lee HW. 2003. Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 22:6023-6031.
10. Kim YH, Park JW, Lee JY, Kwon TK. 2004. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25:1813-1820.
11. Kim S, Kang JK, Kim YK, Seo DW, Ahn SH, Lee JC, Lee CH, You JS, Cho EJ, Lee HW, Han JW. 2006a. Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun 342:1168-1173.
12. Kim YK, Seo DW, Kang DW, Lee HY, Han HW, Kim SN. 2006b. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochem Biophys Res Commun 347:1088-1093.
13. Marks PA, Richon VM, Rifkind RA. 2000. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
14. Marks PA, Richon VM, Miller T, Kelly WK. 2004. Histone deacetylase inhibitors. Adv Cancer Res 91:137-168.
15. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR. 2003. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 278:18980-18989.
16. McLaughlin F, La Thangue NB. 2004. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68:1139-1144.
17. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51.
18. Mizzen CA, Allis CD. 1998. Linking histone acetylation to transcriptional regulation. Cell Mol Life Sci 54:6-20.
19. Ogryzko W, Schiltz RL, Russanova V, Howard BH, Nakatani Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959.
20. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. 1977. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462-464.
21. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D. 1999. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274:34940-34947.
22. Shao Y, Gao Z, Marks PA, Jiang X. 2004. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101:18030-18035.
23. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, Blottiere HM. 2000. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: Induction of cyclin D3 and p21 expression. Gut 46:507-514.
24. Struhl K. 1998. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12:599-606.
25. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. 2001. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7:971-976.
26. Yang J, Kawai Y, Hanson RW, Arinze IJ. 2001. Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Spl sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem 276:25742-25752.
27. Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179.
28. Yuan LW, Soh JW, Weinstein IB. 2002. Inhibition of histone acetyltransferase function of p300 by PKCdelta. Biochim Biophys Acta 1592:205-211.